ClinicalTrials.gg
CompletedNCT05731544Updated Oct 27, 2026

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

A Phase 1/2 interventional study of BMF-219 and Placebo in Type 2 Diabetes Mellitus, sponsored by Biomea Fusion Inc.. Completed at 39 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Biomea Fusion Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2025.
  • Registered 4 months after the study started (first participant enrolled Aug 2022, registered Dec 2022).
Updated Oct 27, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
529th of 2,957
443 · median 90
Started
2022
with 147 others
Phase 1/2
40 of 3,304
3 open now
Registered
2,751st of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 529th largest by enrollment of the 2,957 interventional ones that give a count, is one of 148 that started in 2022, is one of 40 in phase 1/2, and was the 2,751st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.

Read the detailed description

This is a Phase 1/ 2 study that will examine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple dose levels of BMF-219, an orally bioavailable selective covalent inhibitor of menin, in healthy subjects and in subjects with T2D. This study will assess the effect of BMF-219 as single ascending dose (SAD) and multiple ascending dose (MAD), Expansion Cohort will explore 100mg and 200mg dose levels.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes
  • Type 2 Diabetes Mellitus
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Subject Inclusion Criteria:

  1. Males or females, age ≥18 and ≤65 years.
  2. ≥18 and ≤35 kg/m2.
  3. Subjects are healthy on the basis of their medical history, physical examination, , and routine laboratory data.
  4. All subjects must be willing and able to provide written, signed and be willing and able to comply with all study procedures and tests.

Subjects with T2D: (MAD Cohorts) Inclusion Criteria:

  1. Males or females, age ≥18 and ≤65 years.
  2. Diagnosed with T2D within the last 15 years.
  3. Treated with lifestyle management with or without at the most 3 anti-diabetic medications with a stable dose for at least 2 months prior to screening. If on metformin, the stable dose should be at least 500mg/day.
  4. ≥7.0% and ≤10.5%.
  5. BMI ≥25 and ≤40 kg/m2.
  6. Females are to be not pregnant, non-lactating.
  7. All Subjects must be willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.

Subjects with T2D: (Expansion Cohort) Inclusion Criteria:

  1. Males or females, age ≥18 and ≤65 years.
  2. Diagnosed with T2D within the last 7 years.
  3. Treated with lifestyle management with or without at the most 3 anti-diabetic medications with a stable dose for at least 2 months prior to screening. If on metformin, the stable dose should be at least 500mg/day.
  4. HbA1c ≥7.0% and ≤10.5%.
  5. BMI ≥25 and ≤40 kg/m2.
  6. Females are to be not pregnant, non-lactating.
  7. All Subjects must be willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.

Exclusion criteria

Exclusion Criteria:

Healthy Subject Exclusion Criteria:

  1. Evidence or history of any disease or .
  2. Mean ≥ 440 msec on triplicate ECGs. Use of medications known to significantly prolong the QT or QTcF interval.
  3. History of hypertension or untreated hypertension (sitting systolic blood pressure (BP) ≥140 and diastolic BP ≥90 mm Hg).
  4. Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.
  5. History of stomach or intestinal surgery or resection (except appendectomy, hernia repair, and/or cholecystectomy).
  6. A history or evidence of , , or infection at screening or active COVID-19 infection on screening.
  7. Receiving an intervention or having participated in another clinical trial within 30 days.
  8. Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.
  9. Received prior menin inhibitor treatment.

Subjects with T2D (MAD Cohorts) Exclusion Criteria:

  1. Type 1 Diabetes Mellitus or a secondary form of diabetes or any prior history of diabetic ketoacidosis.
  2. Have had recurrence (≥2 episodes) of severe hypoglycemia (defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery) within the last 6 months prior to screening or, has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms as judged by the Investigator.
  3. Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.
  4. Use of anti-diabetes medications (sulfonylureas, insulin, dipeptidyl peptidase-IV inhibitor [DPP-4I] [linagliptin and saxagliptin only] thiazolidinediones) within last 2 months prior to screening.
  5. Fasting plasma glucose ≥255 mg/dL, fasting C-peptide \<0.8 ng/mL, fasting insulin >55 μIU/mL.
  6. Mean QTcF ≥450 ms. Use of medications known to significantly prolong the QT or QTc interval.
  7. Fasting triglyceride ≥500 mg/dL.
  8. Have an \<60 mL/min/1.73 Equation at screening.
  9. or ALT > 1.5 × , > 1.5 × ULN. Isolated GGT elevation >2.5 ULN without > 1.5 x ULN AST, ALT and/or total bilirubin but with a history of abnormal LFTs in the last 6 months or a medical history of a liver disorder should be excluded.
  10. History of acute or chronic pancreatitis and serum lipase and/or amylase above 1.5 x ULN.
  11. Active HBV or active HCV at screening. Known positive test, if any, prior to screening or history of HIV. An active COVID-19 infection at screening.
  12. TSH >6 mIU/L or \<0.4 mIU/L (on stable thyroid replacement dose for 3 months prior to screening).
  13. Severe uncontrolled treated or untreated hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg).
  14. History of stomach or intestinal surgery or resection and/or gastroparesis (except that appendectomy, hernia repair, and/or cholecystectomy will be allowed).
  15. History of cirrhosis.
  16. Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.

Subjects with T2D (Expansion Cohort) Exclusion Criteria:

  1. Type 1 Diabetes Mellitus or a secondary form of diabetes.
  2. Prior history of diabetic ketoacidosis or hyperosmolar coma.
  3. History of severe hypoglycemia (defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery) within the last 6 months prior to screening or, has a history of hypoglycemia unawareness.
  4. Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1 (MEN1).
  5. Use of any of the following anti-diabetes medications within 2 months prior to screening: sulfonylureas, insulin, and the dipeptidyl peptidase-4 inhibitors (DPP4i) linagliptin and saxagliptin (sitagliptin and other DPP4i allowed) thiazolidinones [TZD]) within last 2 months prior to screening.
  6. Fasting plasma glucose ≥255 mg/dL, fasting C-peptide \<0.8 ng/mL, fasting insulin >55 μIU/mL.
  7. Mean QTcF interval >450 ms on triplicate ECGs. Use of prescription or over-the-counter medications known to significantly prolong the QT or QTc interval is excluded.
  8. Fasting triglyceride ≥500 mg/dL.
  9. eGFR\<60 mL/min/1.73.
  10. AST or ALT >1.5 × ULN, Total bilirubin >1.5 × ULN at screening.
  11. History of acute or chronic pancreatitis and serum lipase and/or amylase above 1.5 x ULN.
  12. Active HBV or active HCV at screening. Known positive test or history of HIV. An active COVID-19 infection at screening.
  13. TSH >6 mIU/L or \<0.4 mIU/L (on stable thyroid replacement dose for 3 months prior to screening).
  14. Severe uncontrolled treated or untreated hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg).
  15. History of stomach or intestinal surgery or resection and/or gastroparesis.
  16. History of cirrhosis.
  17. Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    Phase 1 SAD Cohorts

    Phase 1 SAD Cohorts with healthy adults randomized 3:1 receiving BMF-219 or placebo. A pair of sentinel subjects (randomly assigned 1 active drug and 1 placebo) will be dosed 48 hours prior to dosing of the remainder of subjects in each cohort.

    Drug: BMF-219 · Drug: Placebo

  • Experimental
    Phase 1 single dose food effect sub-study

    Phase 1 single dose food effect sub-study with healthy adults randomized 1:1:1:1:1:1 receiving BMF-219 fasted, with a low-fat meal, and with a high fat meal.

    Drug: BMF-219

  • Experimental
    Phase 1 single dose tablet PK sub-study

    Phase 1 single dose x3 PK tablet open-label sub-study with healthy adults randomized 1:1 receiving BMF-219 fasted, with a low-fat meal, and with a high-fat meal).

    Drug: BMF-219

  • Experimental
    Phase 2 MAD Cohorts

    Phase 2 MAD Cohorts with healthy adults (MAD 1, randomized 3:1) or adults with T2D (MAD 2-4 \& 6-8, randomized 5:1) receiving BMF-219 or placebo. MAD 5 is BMF-219 only.

    Drug: BMF-219 · Drug: Placebo

  • Experimental
    Phase 2 Expansion Cohort

    Phase 2 Expansion Cohort adults with T2D randomized 3:1 ratio receiving BMF-219 or placebo.

    Drug: BMF-219 · Drug: Placebo

Interventions

  • Investigational Product

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety Assessments

    Assessed by treatment emergent adverse events. (TEAEs), drug discontinuation due to TEAEs, serious adverse events, clinically significant laboratory, vital, and ECG evaluations.

    Time frame: 52 weeks

  2. Pharmacokinetics Assessments

    Assessed by effect of fed conditions on serial and sparse pharmacokinetic data.

    Time frame: 12 weeks

  3. Change in HbA1c

    Assess the change in HbA1c from baseline to week 26.

    Time frame: 26 weeks

Secondary outcomes

  1. To assess the effect on HbA1c

    Proportion of subjects achieving an HbA1c \< 7% at Week 26.

    Time frame: 26 Weeks

Other outcomes

  1. Exploratory: To determine the effects of BMF-219 on glycemic parameters in subjects with T2D.

    Assess changes in plasma glucose, c-peptide, and insulin at different timepoints by both fasted and in response to OGTT.

    Time frame: Week 26

  2. Exploratory: To determine the impact of multiple ascending doses of BMF-219 on beta-cell function in subjects with T2D.

    Descriptive summaries of homeostatic model assessment beta-cell function %beta and insulin resistance (HOMA-B and HOMA- IR).

    Time frame: Week 26

07

Study locations

39 sites
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Ark Clinical Research, LLC
    Fountain Valley, California 92708, United States
  • Velocity Clinical Research
    La Mesa, California 91942, United States
  • Ark Clinical Research
    Long Beach, California 90815, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Metro Clinical Trials
    San Bernardino, California 92404, United States
  • Southwest General Healthcare Center
    Fort Myers, Florida 33907, United States
  • G+C Research Group
    Hialeah, Florida 33010, United States
  • Sunbright Health Research Centers
    Homestead, Florida 33032, United States
  • Avantis Clinical Research
    Miami, Florida 33155, United States
  • Century Research LLC
    Miami, Florida 33173, United States
  • Entrust Clinical Research
    Miami, Florida 33176, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • David Kavtaradze MD, Inc
    Cordele, Georgia 31015, United States
  • Privia Medical Group
    Savannah, Georgia 31406, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • IMA Clinical Research St. Louis
    St Louis, Missouri 63117, United States
  • Santa Rosa Medical Centers of Nevada
    Las Vegas, Nevada 89119, United States
  • Omera Health
    Brooklyn, New York 11220, United States
  • IMA Clinical Research Manhattan
    New York, New York 10036, United States
  • Carolina Research Center
    Shelby, North Carolina 28150, United States
  • Wake Forest Health Network, LLC, Medical Plaza
    Winston-Salem, North Carolina 27104, United States
  • Diabetes and Endocrinology Associates of Stark County
    Canton, Ohio 44718, United States
  • Medical Care, LLC
    Elizabethton, Tennessee 37643, United States
  • IMA Clinical Research
    Austin, Texas 78745, United States
  • Velocity Clinical Research
    Dallas, Texas 75230, United States
  • Zenos Clinical Research
    Dallas, Texas 75230, United States
  • Synergy Groups Medical LLC
    Houston, Texas 77036, United States
  • Synergy Group Medical
    Houston, Texas 77061, United States
  • Synergy Group Medical
    Missouri City, Texas 77459, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • Diabetes & Glandular Disease Clinic, P.A.
    San Antonio, Texas 78229, United States
  • Simcare Medical Research
    Sugar Land, Texas 77478, United States
  • Velocity Clinical Research
    Waco, Texas 76710, United States
  • Velocity Clinical Research
    Jordan, Utah 84088, United States
  • Manassas Clinical Research
    Manassas, Virginia 20110, United States
  • BC Diabetes
    Vancouver, British Columbia V5Y 3W2, Canada
  • Centricity Research LMC
    Toronto, Ontario M4G 3E8, Canada
  • BioPharma Services Inc.
    Toronto, M9L 3A2, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Nov 2024, 27 months.

Of 41 phase 1/2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 71. This study's 27 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2022
First posted
Feb 16, 2023
StartActual
Aug 17, 2022
Primary completionActual
Nov 18, 2024
CompletionActual
Jul 8, 2025
Results delay requested
Nov 5, 2025
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Drug: Placebo
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Interventions Added Drug: Placebo
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05731544
Lead sponsor
Biomea Fusion Inc.
Responsible party
Sponsor
First posted
Feb 16, 2023
Start date
Aug 17, 2022
Primary completion
Nov 18, 2024
Completion
Jul 8, 2025
Last update
Oct 27, 2026

Study contacts

Biomea Fusion Inc.
study director · Biomea Fusion Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icovamenib

Start the discussion